Mounjaro, differing in its approach, utilizes tirzepatide as its active ingredient, targeting both GLP-1 and GIP receptors, which may, in some cases, enable more significant weight loss compared to Semaglutide GLP-1-based treatments
Boehringer Ingelheim International GmbH Boehringer Ingelheim invests in innovative peptide research and collaborates on GLP-1 related compounds, focusing on improving treatment outcomes for metabolic disorders
Editorial standards At Noom, were committed to providing health information thats grounded in reliable science and expert review
The data tells a clear story
In May 2026, At the EASL Congress 2026, MetaVia presented promising late-breaking Phase 1 clinical trial results for DA-1726, an investigational dual GLP-1 and glucagon receptor agonist under development for obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Heres how to think about legitimacy in three parts: Business legitimacy : Confirmed